Business · 13/07/2020Updated: 10/17/2026 · 1 min read

FDA Releases Final Guidance on Cancer Clinical Trial Eligibility Criteria for HIV, HBV, and HCV Patients

The US Food and Drug Administration (FDA) has released a final guidance for the cancer clinical trial eligibility criteria, focusing on patients with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infections. The guidance aims to increase the inclusion of these patients in cancer clinical trials, potentially accelerating the development of effective therapies.